With limited trial data, a client engaged IQVIA to compare Drug A (emerging therapy) with intensified insulin for T2DM patients uncontrolled on basal insulin. Using OMOP CDM and propensity score matching across EMR datasets, the study analyzed 814 patients per cohort. Results showed Drug A achieved comparable HbA1c control and offered weight advantages. Analysis was completed in six months and leveraged OHDSI tools for consistency. Findings demonstrated Drug A as an effective, tolerable alternative, providing payers and clinicians with real-world evidence for earlier adoption.

Join for free to read